List of Tables
Table 1. Global Immune Checkpoint Inhibitors for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Immune Checkpoint Inhibitors for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Immune Checkpoint Inhibitors for Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Immune Checkpoint Inhibitors for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Immune Checkpoint Inhibitors for Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Immune Checkpoint Inhibitors for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Immune Checkpoint Inhibitors for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Immune Checkpoint Inhibitors for Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Immune Checkpoint Inhibitors for Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of Immune Checkpoint Inhibitors for Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Immune Checkpoint Inhibitors for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Immune Checkpoint Inhibitors for Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Immune Checkpoint Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Immune Checkpoint Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 18. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Region (2021–2026)
Table 19. Global Immune Checkpoint Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 20. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Region (2027–2032)
Table 21. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America Immune Checkpoint Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 27. North America Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 28. North America Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Immune Checkpoint Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Immune Checkpoint Inhibitors for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Immune Checkpoint Inhibitors for Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Immune Checkpoint Inhibitors for Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Immune Checkpoint Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2021–2026)
Table 53. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2027–2032)
Table 54. Global Immune Checkpoint Inhibitors for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Immune Checkpoint Inhibitors for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Type (2021–2026)
Table 59. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Type (2027–2032)
Table 60. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2021–2026)
Table 63. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2027–2032)
Table 64. Global Immune Checkpoint Inhibitors for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Immune Checkpoint Inhibitors for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Application (2021–2026)
Table 69. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Application (2027–2032)
Table 70. Bristol Myers Squibb Company Information
Table 71. Bristol Myers Squibb Description and Business Overview
Table 72. Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Product
Table 74. Bristol Myers Squibb Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Merck Immune Checkpoint Inhibitors for Cancer Product
Table 79. Merck Recent Developments/Updates
Table 80. Regeneron Pharmaceuticals Company Information
Table 81. Regeneron Pharmaceuticals Description and Business Overview
Table 82. Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Product
Table 84. Regeneron Pharmaceuticals Recent Developments/Updates
Table 85. Roche Company Information
Table 86. Roche Description and Business Overview
Table 87. Roche Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Roche Immune Checkpoint Inhibitors for Cancer Product
Table 89. Roche Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AstraZeneca Immune Checkpoint Inhibitors for Cancer Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Innovent Biologics Company Information
Table 96. Innovent Biologics Description and Business Overview
Table 97. Innovent Biologics Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Innovent Biologics Immune Checkpoint Inhibitors for Cancer Product
Table 99. Innovent Biologics Recent Developments/Updates
Table 100. Zydus Company Information
Table 101. Zydus Description and Business Overview
Table 102. Zydus Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Zydus Immune Checkpoint Inhibitors for Cancer Product
Table 104. Zydus Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Immune Checkpoint Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Pfizer Immune Checkpoint Inhibitors for Cancer Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Immune Checkpoint Inhibitors for Cancer Distributors List
Table 113. Immune Checkpoint Inhibitors for Cancer Customers List
Table 114. Immune Checkpoint Inhibitors for Cancer Market Trends
Table 115. Immune Checkpoint Inhibitors for Cancer Market Drivers
Table 116. Immune Checkpoint Inhibitors for Cancer Market Challenges
Table 117. Immune Checkpoint Inhibitors for Cancer Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Immune Checkpoint Inhibitors for Cancer
Figure 2. Global Immune Checkpoint Inhibitors for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Immune Checkpoint Inhibitors for Cancer Market Share by Type: 2025 & 2032
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. CTLA-4 Inhibitors Product Picture
Figure 7. Global Immune Checkpoint Inhibitors for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Immune Checkpoint Inhibitors for Cancer Market Share by Application: 2025 & 2032
Figure 9. Squamous Cell Skin Cancer
Figure 10. Non-small Cell Lung Cancer
Figure 11. Melanoma
Figure 12. Gastric Cancer
Figure 13. Other
Figure 14. Global Immune Checkpoint Inhibitors for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Immune Checkpoint Inhibitors for Cancer Market Size (US$ Million), 2021–2032
Figure 16. Global Immune Checkpoint Inhibitors for Cancer Sales (K Units), 2021–2032
Figure 17. Global Immune Checkpoint Inhibitors for Cancer Average Price (US$/Unit), 2021–2032
Figure 18. Immune Checkpoint Inhibitors for Cancer Report Years Considered
Figure 19. Immune Checkpoint Inhibitors for Cancer Sales Share by Manufacturers in 2025
Figure 20. Global Immune Checkpoint Inhibitors for Cancer Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Immune Checkpoint Inhibitors for Cancer Players: Market Share by Revenue in Immune Checkpoint Inhibitors for Cancer in 2025
Figure 22. Immune Checkpoint Inhibitors for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Immune Checkpoint Inhibitors for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 25. North America Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 26. United States Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 29. Europe Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 30. Germany Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2021–2032)
Figure 37. China Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 45. Latin America Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Immune Checkpoint Inhibitors for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Immune Checkpoint Inhibitors for Cancer by Type (2021–2032)
Figure 56. Global Revenue Market Share of Immune Checkpoint Inhibitors for Cancer by Type (2021–2032)
Figure 57. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Immune Checkpoint Inhibitors for Cancer by Application (2021–2032)
Figure 59. Global Revenue Market Share of Immune Checkpoint Inhibitors for Cancer by Application (2021–2032)
Figure 60. Global Immune Checkpoint Inhibitors for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 61. Immune Checkpoint Inhibitors for Cancer Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
